0000080255-23-002736.txt : 20230214
0000080255-23-002736.hdr.sgml : 20230214
20230214123817
ACCESSION NUMBER: 0000080255-23-002736
CONFORMED SUBMISSION TYPE: SC 13G/A
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Longboard Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001832168
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 845009619
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-92379
BUSINESS ADDRESS:
STREET 1: 4275 EXECUTIVE SQUARE
STREET 2: SUITE 950
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 619-592-9775
MAIL ADDRESS:
STREET 1: 4275 EXECUTIVE SQUARE
STREET 2: SUITE 950
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: PRICE T ROWE ASSOCIATES INC /MD/
CENTRAL INDEX KEY: 0000080255
STANDARD INDUSTRIAL CLASSIFICATION: SECURITY & COMMODITY BROKERS, DEALERS, EXCHANGES & SERVICES [6200]
IRS NUMBER: 520556948
STATE OF INCORPORATION: MD
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 100 EAST PRATT ST
CITY: BALTIMORE
STATE: MD
ZIP: 21202
BUSINESS PHONE: (410)345-2000
MAIL ADDRESS:
STREET 1: P.O. BOX 89000
CITY: BALTIMORE
STATE: MD
ZIP: 21289
SC 13G/A
1
lbph13gadec22.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)
LONGBOARD PHARMACEUTICALS IN
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
54300N103
(CUSIP NUMBER)
December 31, 2022
(Date of Event which Requires Filing of Statement)
Check the appropriate box to designate the Rule pursuant to which this
Schedule is filed:
[x] Rule 13d - 1(b)
Rule 13d - 1(c)
Rule 13d - 1(d)
1. Name of Reporting Person
T. ROWE PRICE ASSOCIATES, INC.
52-0556948
2. Check the Appropriate Box if a Member of a Group
NOT APPLICABLE
3. SEC Use Only
4. Citizenship or Place of Organization
Maryland
Number of Shares Beneficially Owned by Each Reporting Person With
5. Sole Voting Power* 169,741
6. Shared Voting Power* 0
7. Sole Dispositive Power* 1,510,961
8. Shared Dispositive Power 0
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,510,961
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
NOT APPLICABLE
11. Percent of Class Represented by Amount in Row 9
11.1%
12. Type of Reporting Person
IA
*Any shares reported in Items 5 and 6 are also reported in Item 7.
1. Name of Reporting Person
T. ROWE PRICE NEW HORIZONS FUND, INC.
52-0791372
2. Check the Appropriate Box if a Member of a Group
NOT APPLICABLE
3. SEC Use Only
4. Citizenship or Place of Organization
Maryland
Number of Shares Beneficially Owned by Each Reporting Person With
5. Sole Voting Power* 766,683
6. Shared Voting Power* 0
7. Sole Dispositive Power* 0
8. Shared Dispositive Power 0
9. Aggregate Amount Beneficially Owned by Each Reporting Person
766,683
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
NOT APPLICABLE
11. Percent of Class Represented by Amount in Row 9
5.6%
12. Type of Reporting Person
IV
*Any shares reported in Items 5 and 6 are also reported in Item 7.
Item 1(a) Name of Issuer:
LONGBOARD PHARMACEUTICALS IN
Item 1(b) Address of Issuer's Principal Executive Offices:
4275 EXECUTIVE SQUARE, SUITE 950, LA JOLLA, CALIFORNIA 92037
Item 2(a) Name of Person(s) Filing:
(1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates)
(2) T. ROWE PRICE NEW HORIZONS FUND, INC.
X Attached as Exhibit A is a copy of an agreement between the Persons Filing
(as specified hereinabove) that this Schedule 13G is being filed on behalf
of each of them.
Item 2(b) Address of Principal Business Office:
100 E. Pratt Street, Baltimore, MD 21202
Item 2(c) Citizenship or Place of Organization:
(1) Maryland
(2) Maryland
Item 2(d) Title of Class of Securities: COMMON STOCK
Item 2(e) Cusip Number: 54300N103
Item 3: The person filing this Schedule 13G is an:
X Investment Adviser registered under Section 203 of the Investment
Advisers Act of 1940
X Investment Company registered under Section 8 of the Investment
Company Act of 1940
Item 4: Reference is made to Items 5-11 on the preceding pages of this
Schedule 13G.
Item 5: Ownership of Five Percent or Less of a Class
Not Applicable
Item 6: Ownership of More than Five Percent on Behalf of Another Person
(1) Price Associates does not serve as custodian
of the assets of any of its clients; accordingly, in each
instance only the client or the client's custodian or
trustee bank has the right to receive dividends paid with
respect to, and proceeds from the sale of, such securities.
The ultimate power to direct the receipt of dividends paid with
respect to, and the proceeds from the sale of, such securities, is
vested in the individual and institutional clients which
Price Associates serves as investment adviser.
Any and all discretionary authority which has been delegated to
Price Associates may be revoked
in whole or in part at any time.
Except as may be indicated if this is a joint filing with one of the
registered investment companies sponsored by
Price Associates which it also serves as
investment adviser ("T. Rowe Price Funds"), not more
than 5% of the class of such securities is owned by any one client
subject to the investment advice of Price Associates.
(2) With respect to securities owned by any one of the T. Rowe Price
Funds, only the custodian for each of such Funds, has the right to
receive dividends paid with respect to, and proceeds from the sale of,
such securities. No other person is known to have such right, except
that the shareholders of each such Fund participate proportionately
in any dividends and distributions so paid.
Item 7: Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company.
Not Applicable
Item 8: Identification and Classification of Members of the Group
Not Applicable
Item 9: Notice of Dissolution of Group
Not Applicable
Item 10: Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired and are not
held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.
T. Rowe Price Associates, Inc. hereby declares and affirms
that the filing of Schedule 13G shall not be construed as an admission
that Price Associates is the beneficial owner of the
securities referred to, which beneficial ownership is expressly
denied.
Signature.
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
T. ROWE PRICE ASSOCIATES, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
T. ROWE PRICE NEW HORIZONS FUND, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
12/31/2022
EXHIBIT A
AGREEMENT
JOINT FILING OF SCHEDULE 13G
Price Associates, Inc. (an investment adviser
registered under the Investment Advisers Act of 1940), and
T. ROWE PRICE NEW HORIZONS FUND, INC.,
all of which are Maryland corporations, hereby agree to file jointly the
statement on Schedule 13G to which this Agreement is attached, and any
amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G
under the Securities Exchange Act of 1934.
It is understood and agreed that each of the parties hereto is responsible for
the timely filing of such statement and any amendments thereto, and for the
completeness and accuracy of the information concerning such party contained
therein, but such party is not responsible for the completeness or accuracy of
information concerning the other party unless such party knows or has reason to
believe that such information is inaccurate.
It is understood and agreed that a copy of this Agreement shall be attached as
an exhibit to the statement on Schedule 13G, and any amendments hereto, filed
on behalf of each of the parties hereto.
T. ROWE PRICE ASSOCIATES, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President
T. ROWE PRICE NEW HORIZONS FUND, INC.
Date: February 14, 2023
Signature: /s/ David Oestreicher
Name & Title: David Oestreicher, Executive Vice President